Project Grant R01HL171594
Award Date 9/1/25
Completion Date 5/31/29
Dollars Obligated $375K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,963 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New Health Sciences, Inc. (Hemanext Inc.) to evaluate the hemostatic function of platelets stored under hypoxic conditions for whole blood (WB) transfusion. The project aims to develop an improved WB storage platform that maintains an oxygen-managed environment to provide higher quality red blood cells for oxygen delivery and shock reversal, while...
- This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $693,423 to Baylor College of Medicine to develop and validate a novel microfluidic device capable of purifying platelets for pediatric and neonatal transfusions. The goal is to create a simple, disposable device that can effectively remove contaminants from platelet suspensions while preserving high-functioning platelets. The project will optimize the efficiency of...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of platelet ABO(H) blood group antigens in hemostasis and thrombosis. The $445,708 award to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, will fund a 3-year research project to: 1) define the impact of ABO(H) glycans on platelet binding to von Willebrand factor, and 2) identify ABO(H) antigen-carrying glycoproteins...
- This Project Grant award of $944,676 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel platelet-inspired nanotechnology called Synthoplate (SP) by Haima Therapeutics LLC. The goal is to restore hemostasis, or normal blood clotting function, in patients on antiplatelet agents like clopidogrel and ticagrelor who suffer from traumatic brain injuries. This is a critical unmet need, as...
- This $568,264 Project Grant (R41HL178144) was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company based in Cambridge, MA. The goal of this Phase I STTR project is to develop a scalable bioprocess for manufacturing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). These designer RBCs will serve as reagents to...
- This $604,301 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Versiti Wisconsin, Inc. will support research on membrane-cytoskeleton interactions in megakaryocytes and platelets. The research aims to advance the understanding of abnormal platelet production and function, which can pose significant clinical risks including bleeding and thrombotic events. The project will investigate the precise molecular mechanisms...
- This Project Grant award, valued at $465,000.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research to investigate the mechanisms by which chronic inflammation disrupts the hemostatic balance in sickle cell disease (SCD). Specifically, the project aims to understand how tumor necrosis factor-alpha (TNFa) induced inflammation blocks autophagy and mitophagy in platelets and...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Texas Tech University System provides $587,878 to develop novel additive-manufactured devices for label-free magnetophoresis to fractionate red blood cells (RBCs). The research aims to separate healthy, hemoglobin-enriched RBCs from damaged or iron-deficient cells to extend the shelf life of RBC units and enable transfusion therapies that can alleviate negative effects...
- This $457,514 Project Grant award was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Thomas Jefferson University, doing business as Sidney Kimmel Medical College. The grant funding supports research to investigate the role of platelet activation in maintaining hemostasis and reducing bleeding in coagulation disorders. The proposed studies will explore mechanisms by which reduced thrombin production limits platelet-mediated hemostatic...